All relevant data are within the manuscript and its Supporting Information files.

Background {#sec005}
==========

Protective sterilizing immunity against malaria has been achieved in malaria-naïve humans following immunization with attenuated merozoites \[[@pone.0228177.ref001],[@pone.0228177.ref002]\], irradiated *P*. *falciparum* sporozoites \[[@pone.0228177.ref003],[@pone.0228177.ref004]\] or with live sporozoites under chloroquine prophylaxis before the establishment of blood stage infection \[[@pone.0228177.ref005],[@pone.0228177.ref006]\]. Though there are no clearly defined correlates of protection against clinical malaria by these vaccines, immune mechanisms mediating protection may include interferon-γ (IFN-γ)-secreting CD8+ T cells that primarily target malaria antigens expressed on the surface of hepatocytes \[[@pone.0228177.ref007]--[@pone.0228177.ref009]\]. Despite the near 100% sterile protection achieved by these vaccines against homologous parasite strains, recent evidence suggest that whole sporozoite vaccines may have to include sporozoites from multiple parasite strains to induce long-term broad protection \[[@pone.0228177.ref010],[@pone.0228177.ref011]\]. This approach however introduces new challenges with increased production cost and appropriate dosing.

An alternative approach to whole sporozoite immunization is to identify immunodominant epitopes within essential target parasite antigens for the development of multi-epitope subunit vaccines. This vaccine design only requires the production and formulation of short linear peptides or their corresponding DNA sequences, enabling multiple antigens from different parasite strains to be included in a single vaccine. In addition, relatively lower doses will be required for the induction of optimal protective responses \[[@pone.0228177.ref012],[@pone.0228177.ref013]\]. Such immunodominant HLA-restricted T cell peptides from essential parasite antigens have been identified in immunized malaria-naïve individuals \[[@pone.0228177.ref014]--[@pone.0228177.ref016]\]. Initial assessment of vaccines designed on this basis have shown promising results \[[@pone.0228177.ref017]--[@pone.0228177.ref019]\].

Induction of sporozoite-specific CD8+ T cell responses requires the processing and presentation of sporozoite antigen peptides on infected hepatocytes via HLA class I molecules \[[@pone.0228177.ref020]\]. The genetic diversity within human HLA molecules could present a challenge to the development of broadly effective epitope-based vaccines. This can however be overcome by targeting parasite peptides that can be recognized and presented by multiple HLA class I supertypes \[[@pone.0228177.ref021]\].

Circumsporozoite protein (CSP) is the most abundant protein expressed on the surface of *Plasmodium* sporozoites and plays a crucial role in the invasion of hepatocytes \[[@pone.0228177.ref022]\]. It is the parasite component of RTS,S, the most advanced malaria vaccine. Previous studies with nine pools of 15mer overlapping peptides covering the entire 3D7 strain CSP antigen identified four pools (Cp1, Cp4, Cp6, Cp9) that induced positive IFN-ɣ responses among Ghanaian adult subjects with a history of *Plasmodium* infections over their life time \[[@pone.0228177.ref023],[@pone.0228177.ref024]\]. Since each of these pools contained multiple 15mer peptides, the next step is to determine the minimal (8-10mer) epitope(s) that are ultimately responsible for the observed positive pool-specific responses.

The aim of this study was to experimentally assess the induction and T cell subset-specificity of IFN-γ responses by selected 8-10mer single peptides from *P*. *falciparum* CSP using PBMCs from HLA-typed subjects with natural exposure to malaria. The selected peptides have been predicted by bioinformatics algorithms to bind to defined HLA types and/or were present in peptide pools that previously tested positive in ELISpot assays \[[@pone.0228177.ref023],[@pone.0228177.ref024]\]. Overall, we identified four HLA-promiscuous and relatively conserved peptides that induce CD8+ T cell-specific IFN-γ responses.

Methods {#sec006}
=======

Ethics {#sec007}
------

This study was conducted at the Noguchi Memorial Institute for Medical Research (NMIMR) according to a human research protocol that was approved by the NMIMR Institutional Review Board (Protocol number 042/13-14). The NMIMR-IRB holds a US Government Federal-wide Assurance (FWAA00001824) from the US Office for Human Research Protections. Written informed consent was sought from all study subjects who willingly agreed to be part of the study and met the inclusion criteria. All study procedures were performed in accordance with the ethical standards of the Helsinki Declaration.

Study site and participants {#sec008}
---------------------------

The study was conducted within the Legon community in Accra, Ghana, where malaria transmission is limited mainly to the rainy season, typically from March to November. PBMCs from nine participants aged between 25 and 45 years, recruited between November 2013 and March 2014, were used in this study. These participants were from a pool of about 20 subjects who had previously participated in ELISpot standardization studies conducted jointly by NMIMR and the Naval Medical Research Center (NMRC), USA, and their HLA supertype data were available. Eligibility criteria for the current study were as follows: age 18--55 years, normal screening medical history and physical examination, haemoglobin \>10 g/dl, absence of known immunodeficiency (\> 400 CD4+ T cells/μl of blood) and availability of enough cryopreserved PBMCs for conduct of assays. On the basis of these, PBMCs from nine HLA typed subjects were available for inclusion in this study. At the time of blood draw, study subjects were screened for malaria parasites by light microscopy.

Sample collection and processing {#sec009}
--------------------------------

Blood sample collection and PBMC isolation were performed as previously described \[[@pone.0228177.ref024],[@pone.0228177.ref025]\] and PBMCs were stored in 20 million cells/ml aliquots in liquid nitrogen. For the current study, PBMCs were thawed at 37°C, washed twice with R5 medium (RPMI-1640 with 5% foetal calf serum, 1% penicillin-streptomycin) and allowed to rest in an incubator at 37°C, 5% CO~2~ for up to 8 hours. After this period, PBMCs were again washed and re-suspended in HR10 medium (RPMI 1640 supplemented with 10% normal human serum, 1% penicillin-streptomycin, 1% glutamine) before use in ELISpot assays. For each subject, concentration of the PBMC suspension was adjusted to 4 million/ml before use in assays (final concentration of 400,000 cells/well).

Negative selection of CD8+ T cell fraction of PBMCs {#sec010}
---------------------------------------------------

To confirm that CD8+ T cells responded to peptide stimulants, the CD8+ T cell fraction of PBMCs was enriched by a negative selection protocol that depleted cell types expressing the CD4 receptor, including CD4+ T cells. This was carried out with the anti-human MyOne^™^ SA Dynabeads® kit (Invitrogen, Life Technologies) and following the bead manufacturer's instructions. In brief, a cocktail of biotinylated mouse anti-human antibodies against non-CD8+ T cells was added to thawed and washed PBMCs at the required concentration for ELISpot (4 million cells/ml) and incubated for 20 minutes. PBMCs were subsequently incubated with streptavidin-conjugated anti-human MyOne^™^ SA dynabeads for 15 minutes at 25°C and CD8+ cells separated from non-CD8+ cells in a magnetic field.

Flow cytometry was used to confirm the effectiveness of the CD8+ T cell enrichment procedure. Three microliters (3 μl) each of mouse anti-human CD4 and CD8 antibodies (BD Pharmingen) were respectively added to 100 μl of whole and CD8+ T cell-enriched PBMCs. The cells were incubated at 4°C for 20 minutes and washed with 2 ml of R5 medium. Cells were reconstituted in 250 μl of FACs buffer (BD FACSFlow) and acquired (100,000 events) on a BD FACSCalibur machine. Data analysis was performed using the CellQuest^™^ Pro software (version 6).

The CD8+ T cell-enriched PBMC fraction was then re-suspended in the same starting volume of HR10 medium and used in ELISpot assays (described below) alongside the unfractionated PBMCs.

Synthetic peptides {#sec011}
------------------

Whole and CD8+ T cell-enriched PBMCs were stimulated with 8-10mer single peptides from the 3D7 *P*. *falciparum* CSP antigen (GenBank accession number X15363). Twenty three 8-10mer CSP peptides were selected either on the basis of being present in peptide pools that gave positive ELISpot responses previously (Cp1, Cp4, Cp6 and Cp9, \[[@pone.0228177.ref023],[@pone.0228177.ref024]\]), and/or having been predicted (NetMHC) to be restricted by subject HLA-A or HLA-B allele types ([Table 1](#pone.0228177.t001){ref-type="table"}). The NetMHC algorithm \[[@pone.0228177.ref026]\] predictions were performed as previously described \[[@pone.0228177.ref024]\]. Peptides were synthesized by Alpha Diagnostics Inc. (San Antonio, TX, USA) to a purity of \> 90%. The locations of the 23 peptides within the previously tested 15mer peptides \[[@pone.0228177.ref023],[@pone.0228177.ref024]\] are presented in [Table 1](#pone.0228177.t001){ref-type="table"}. All peptides were diluted to the required concentration with HR10 medium for use in ELISpot assays.

10.1371/journal.pone.0228177.t001

###### Peptides used to stimulate study subject PBMCs.

![](pone.0228177.t001){#pone.0228177.t001g}

  Subject   HLA types      Peptides       Amino acids   CSP pool[^\#^](#t001fn002){ref-type="table-fn"}   Subject        HLA types      Peptides      Amino acids   CSP pool[^\#^](#t001fn002){ref-type="table-fn"}
  --------- -------------- -------------- ------------- ------------------------------------------------- -------------- -------------- ------------- ------------- -------------------------------------------------
  v01                      `ILSVSSFLFV`   7--16         Cp1                                               v05            A03            `LAILSVSSF`   5--13         Cp1
            `MPNDPNRNV`    285--293       Cp5           B07/B44                                           `FVEALFQEY`    15--23         Cp1                         
  A02       `HIKEYLNKI`    315--323       Cp6                                                             `RIKPGSANK`    345--353       Cp7                         
  B07/B44   `YLNKIQNSL`    319--327       Cp6           v06                                                              `LAILSVSSF`    5--13         Cp1           
            `SVFNVVNSSI`   376--385       Cp9                                                             `SVSSFLFVEA`   9--18          Cp1                         
            `GLIMVLSFL`    386--394       Cp9                                                             `FVEALFQEY`    15--23         Cp1                         
  v02                      `MMRKLAILSV`   1--10         Cp1                                               A01/A02        `NYDNAGTNLY`   39--48        Cp2           
            `ILSVSSFLFV`   7--16          Cp1           B07                                               `LYNELEMNYY`   47--56         Cp2                         
            `FVEALFQEY`    15--23         Cp1                                                             `SVTCGNGIQV`   335--343       Cp7                         
  A01/A02   `NYDNAGTNLY`   39--48         Cp2                                                             `SVFNVVNSSI`   376--385       Cp9                         
  B07/B44   `LYNELEMNYY`   47--56         Cp2                                                             `SSIGLIMVL`    383--391       Cp9                         
            `YLNKIQNSL`    319--327       Cp6           v07                                               A03/A24        `LAILSVSSF`    5--13         Cp1           
            `GLIMVLSFL`    386--394       Cp9           B07                                               `SFLFVEALF`    12--20         Cp1                         
  v03       A01/A03        `MPNDPNRNV`    285--293      Cp5                                               v08                           `ALFQEYQCY`   18--26        Cp1
  B07       `HIKEYLNKI`    315--323       Cp6                                                             `NYDNAGTNLY`   39--48         Cp2                         
            `RIKPGSANK`    345--353       Cp7                                                             `LYNELEMNYY`   47--56         Cp2                         
  v04                      `MMRKLAILSV`   1--10         Cp1                                               A01/A03        `YLNKIQNSL`    319--327      Cp6           
            `ILSVSSFLFV`   7--16          Cp1           B27                                               `IQNSLSTEW`    323--331       Cp6                         
            `SVSSFLFVEA`   9--18          Cp1                                                             `KMEKCSSVF`    370--378       Cp9                         
            `FLFVEALFQE`   13--22         Cp1                                                             `IMVLSFLFL`    388--396       Cp9                         
  A02       `YLNKIQNSL`    319--327       Cp6           v09                                                              `LAILSVSSF`    5--13         Cp1           
            `SVTCGNGIQV`   335--343       Cp7                                                             `MPNDPNRNV`    285--293       Cp5                         
            `SVFNVVNSSI`   376--385       Cp9           B07/B58                                           `IQNSLSTEW`    323--331       Cp6                         
            `GLIMVLSFL`    386--394       Cp9                                                             `SSIGLIMVL`    383--391       Cp9                         
                                                                                                                         `LIMVLSFLF`    387--395      Cp9           

Peripheral blood mononuclear cells (PBMCs) from were stimulated with the 8-10mer peptides indicated for each subject. Peptides were predicted to bind to the subjects' indicated HLA types using the artificial neural network-based NetMHC algorithm.

\# Indicates the CSP 15mer overlapping peptide pool, as described by Ganeshan et al.\[[@pone.0228177.ref024]\] that contains the predicted -10mer peptide

*Ex vivo* ELISpot IFN-γ assays {#sec012}
------------------------------

IFN-γ ELISpot assays were performed as previously described \[[@pone.0228177.ref024]\] using cryopreserved PBMCs. PBMCs (unfractionated and the CD8+ T cell-enriched fraction) from subjects were tested in triplicate with 10 μg/ml each of subject-specific CSP peptides. Phytohaemaglutinin (PHA, Sigma Aldrich, USA) (1 μg/ml), concanavalin A (Con A, Sigma Aldrich, USA) (0.625 μg/ml) and a pool of HLA class I-restricted T cell epitopes from common viruses (CEF, Cellular Technology Ltd, USA) (2.0 μg/ml) were used as positive controls and subject PBMCs incubated with culture medium only were used as negative controls. After substrate incubation and plate development, the number of IFN-γ-producing cells was estimated using an automated ELISpot plate reader (AID GmbH, Germany) and the data exported into Microsoft Excel for analysis.

Data analysis {#sec013}
-------------

The mean of replicate readings for each stimulant was calculated and activities were expressed as spot forming cells per million (sfc/m) PBMCs. Any single value for the triplicate readings of each stimulant/control that contributed more than 50% of the standard deviation of the triplicate and was at least three times greater or less than the mean of the remaining two values was considered an outlier and discarded. The assay was considered positive if there was (1) at least a doubling of sfc/m in test wells relative to control wells, and (2) a difference of at least ten spots between test and control wells. This definition was validated and adapted for use in previous studies \[[@pone.0228177.ref024],[@pone.0228177.ref025]\].

Results {#sec014}
=======

IFN-ɣ responses in whole PBMC fractions {#sec015}
---------------------------------------

All subjects used in this study had a normal medical history at screening and were negative for malaria by light microscopy. Cryopreserved PBMCs from the nine subjects were retrieved and used in this study. For analysis and comparison, IFN-ɣ ELISpot response (sfc/m) for the unstimulated PBMC control are subtracted from the responses for each test peptide. All subjects responded positively to the mitogens Con A (response range 75--379 sfc/m, after unstimulated background subtraction) and PHA (122--467 sfc/m) but as expected, responses of individual subjects to CEF were variable, ranging from no response (v08, 0 sfc/m), a low response (v09, 25 sfc/m) to high responses (v01 to v07, 233--513 sfc/m). In all assays, unstimulated medium control was low and responses ranged between 1 and 24 sfc/m PBMCs.

A total of 23 peptides were used to stimulate PBMCs from the nine study subjects. The least number of peptides tested per subject was two for subject v07 whilst the highest number tested per subject was eight for each of subjects v04, v06 and v08 ([Table 2](#pone.0228177.t002){ref-type="table"}). In all, five subjects responded to a total of ten peptides: subject v03 responded to three peptides (`MPNDPNRNV`, `HIKEYLNKI` and `RIKPGSANK`), subject v04 responded to three peptides (`SVSSFLFVEA`, `FLFVEALFQE`, `GLIMVLSFL`), subject v07 responded to two peptides (`LAILSVSSF` and `SFLFVEALF`), subject v08 responded to one peptide (`YLNKIQNSL`) and subject v09 responded to two peptides (`LAILSVSSF` and `IQNSLSTEW`) ([Table 2](#pone.0228177.t002){ref-type="table"}). Thus two subjects (v04 and v09) made responses to peptide `LAILSVSSF`. Of the ten positive responses, subject v07's response to peptide `SFLFVEALF` recalled the highest activity (38 sfc/m PBMCs), while subjects v04 and v08 had the lowest activities (10 sfc/m PBMCs) after unstimulated background subtraction. IFN-ɣ responses of the four remaining subjects did not meet our positivity definition criteria.

10.1371/journal.pone.0228177.t002

###### Interferon gamma responses by unfractionated PBMCs to the 8-10mer CSP peptide peptides.

![](pone.0228177.t002){#pone.0228177.t002g}

  Subject   HLA types          Stimulants        sfc/m     Response   Subject           HLA types         Stimulants    sfc/m     Response
  --------- ------------------ ----------------- --------- ---------- ----------------- ----------------- ------------- --------- ----------
  v01                          `ILSVSSFLFV`      27        neg        v05               A03               `LAILSVSSF`   24        neg
            `MPNDPNRNV`        18                neg       B07/B44    `FVEALFQEY`       24                neg                     
  A02       `HIKEYLNKI`        26                neg                  `RIKPGSANK`       13                neg                     
  B07/B44   `YLNKIQNSL`        23                neg                  Medium            10                                        
            `SVFNVVNSSI`       22                neg       v06                          `LAILSVSSF`       6             neg       
            `GLIMVLSFL`        25                neg                  `SVSSFLFVEA`      6                 neg                     
            Medium             17                          A01/A02    `FVEALFQEY`       7                 neg                     
  v02                          `MMRKLAILSV`      12        neg        B07               `NYDNAGTNLY`      6             neg       
  A01/A02   `ILSVSSFLFV`       8                 neg                  `LYNELEMNYY`      6                 neg                     
  B07/B44   `FVEALFQEY`        7                 neg                  `SVTCGNGIQV`      6                 neg                     
            `NYDNAGTNLY`       5                 neg                  `SVFNVVNSSI`      6                 neg                     
            `LYNELEMNYY`       13                neg                  `SSIGLIMVL`       6                 neg                     
            `YLNKIQNSL`        11                neg                  Medium            6                                         
            `GLIMVLSFL`        7                 neg       v07        A03/A24           **`LAILSVSSF`**   **33**        **POS**   
            Medium             4                           B07        **`SFLFVEALF`**   **53**            **POS**                 
  v03       A01/A03            **`MPNDPNRNV`**   **23**    **POS**                      Medium            15            ** **     
  B07       **`HIKEYLNKI`**    **26**            **POS**   v08                          `LAILSVSSF`       3             neg       
            **`RIKPGSANK`**    **31**            **POS**              `ALFQEYQCY`       5                 neg                     
            Medium             9                 ** **                `NYDNAGTNLY`      3                 neg                     
  v04                          `MMRKLAILSV`      8         neg        A01/A03           `LYNELEMNYY`      3             neg       
            `ILSVSSFLFV`       13                neg       B27        **`YLNKIQNSL`**   **13**            **POS**                 
            **`SVSSFLFVEA`**   **18**            **POS**              `IQNSLSTEW`       3                 neg                     
  A02       **`FLFVEALFQE`**   **23**            **POS**              `KMEKCSSVF`       5                 neg                     
            `YLNKIQNSL`        13                neg                  `IMVLSFLFL`       6                 neg                     
            `SVTCGNGIQV`       11                neg                  Medium            3                                         
            `SVFNVVNSSI`       12                neg       v09                          **`LAILSVSSF`**   **50**        **POS**   
            **`GLIMVLSFL`**    **33**            **POS**   A01/A03    `MPNDPNRNV`       45                neg                     
            Medium             8                 ** **     B07/B58    **`IQNSLSTEW`**   **48**            **POS**                 
                                                                                        `SSIGLIMVL`       39            neg       
                                                                                        `LIMVLSFLF`       41            neg       
                                                                                        Medium            24                      

Peptides were used to stimulate subject PBMCs (400,000 cells/well) in triplicate, and the number of cells that were actively secreting peptide-specific IFN-ɣ enumerated and expressed as the average number of spot forming cells per million (sfc/m) PBMCs. The presented sfc/m data are the absolute counts and the medium/background responses. Response positivity criteria have been described under the "Methods" section. POS = a positive peptide response, also indicated in bold, neg = negative peptide response.

IFN-ɣ responses in CD8+ T cell-enriched PBMCs {#sec016}
---------------------------------------------

There were sufficient cryopreserved PBMC from eight of the nine study subjects for CD8+ T cell enrichment studies. CD8+ T cell enrichment was assessed by surface staining for CD4 and CD8 receptors and flow cytometry. The proportion of CD4+ T cells reduced from 42.1 ± 8.8% in the unfractionated population to 1.3 ± 1.1% after depletion, while that of CD8+ T cells increased from 28.4 ± 6.4% in the unfractionated population to 66.2 ± 11.1% after enrichment. Representative data for one of the study subjects is presented in [S1 Fig](#pone.0228177.s001){ref-type="supplementary-material"}.

In assays with CD8+ enriched cells, five of the nine subjects responded to Con A (response range 16--213 sfc/m after medium/background subtraction), six responded to PHA (57--372 sfc/m) and 5 responded to CEF (26--311 sfc/m). All subjects responded to at least two of the three positive control stimulants, with one subject each responding to only one of the three stimulants. Unstimulated medium control responses for assays with CD8+ enriched cells ranged between 1 and 21 sfc/m PBMCs.

Of the ten peptides that yielded positive ELISpot responses in unfractionated subject PBMCs, three peptides remained positive with the CD8+ T cell-enriched PBMC fraction from the same subjects ([Table 3](#pone.0228177.t003){ref-type="table"}); subject v03 remained positive to two of the three peptides that were previously positive (`MPNDPNRNV` and `RIKPGSANK`) while subject v04 remained positive to peptide `GLIMVLSFL`. In addition, two peptides that were previously negative with unfractionated PBMCs gave positive responses with the CD8-enriched PBMC fractions; v04 tested positive against peptide `SVFNVVNSSI` and v05 tested positive against peptide `RIKPGSANK`. Thus a total of four peptides tested positive against the CD8+ T cell-enriched fraction of PBMCs, and these peptides are most likely presented by HLA class I molecules to CD8+ T cells. The four positive peptides are from the C-terminal of the protein and show limited polymorphism ([Fig 1](#pone.0228177.g001){ref-type="fig"}). By extension, the loss of positive peptide responses against CD8+ T cell-enriched PBMC fractions from some subjects (a total of seven peptides for subjects v03, v04, v07, v08 and v09) suggests that those peptides are likely to be presented by HLA class II molecules to CD4+ T cells, or that they did not meet the criteria for response positivity.

![Alignment of PfCSP sequences from multiple Pf strains.\
Sequences include those from established laboratory parasite strains as well field isolates from Ghana, Nigeria, Venezuela, Thailand. Dash lines represent the conserved residues relative to the 3D7 consensus from which tested peptides were derived. Dots represent deleted sequences compared to the Wellcome sequence, which is the longest in terms of amino acid residues (442). The final four peptides identified as being immunodominant in this study are highlighted in different colours. Sequences were sourced from Genbank and UniProt sequence databases, and alignments to identify deleted residues in some sequences were done in UniProt.](pone.0228177.g001){#pone.0228177.g001}

10.1371/journal.pone.0228177.t003

###### Interferon-gamma responses by CD8+ PBMC fractions to the 8-10mer CSP peptides.
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  Subject   HLA types          Stimulants        sfc/m     Response   Subject        HLA types     Stimulants    sfc/m   Response
  --------- ------------------ ----------------- --------- ---------- -------------- ------------- ------------- ------- ----------
  v02                          `MMRKLAILSV`      10        neg        v06                          `LAILSVSSF`   1       neg
            `ILSVSSFLFV`       9                 neg                  `SVSSFLFVEA`   1             neg                   
  A01/A02   `FVEALFQEY`        6                 neg                  `FVEALFQEY`    4             neg                   
  B07/B44   `NYDNAGTNLY`       10                neg       A01/A02    `NYDNAGTNLY`   2             neg                   
            `LYNELEMNYY`       6                 neg       B07        `LYNELEMNYY`   2             neg                   
            `YLNKIQNSL`        12                neg                  `SVTCGNGIQV`   1             neg                   
            `GLIMVLSFL`        6                 neg                  `SVFNVVNSSI`   1             neg                   
            Medium             6                                      `SSIGLIMVL`    2             neg                   
  v03                          **`MPNDPNRNV`**   **36**    **POS**                   Medium        1                     
  A01/A03   `HIKEYLNKI`        28                neg       v07        A03/A24        `LAILSVSSF`   15            neg     
  B07       **`RIKPGSANK`**    **39**            **POS**   B07        `SFLFVEALF`    21            neg                   
            Medium             16                ** **                Medium         12                                  
  v04                          `MMRKLAILSV`      8         neg        v08                          `LAILSVSSF`   4       neg
            `ILSVSSFLFV`       6                 neg                  `ALFQEYQCY`    3             neg                   
            `SVSSFLFVEA`       12                neg                  `NYDNAGTNLY`   3             neg                   
            `FLFVEALFQE`       12                neg       A01/A03    `LYNELEMNYY`   3             neg                   
  A02       `YLNKIQNSL`        7                 neg       B27        `YLNKIQNSL`    3             neg                   
            `SVTCGNGIQV`       10                neg                  `IQNSLSTEW`    4             neg                   
            **`SVFNVVNSSI`**   **16**            **POS**              `KMEKCSSVF`    4             neg                   
            **`GLIMVLSFL`**    **43**            **POS**              `IMVLSFLFL`    3             neg                   
            Medium             5                 ** **                Medium         3                                   
  v05                          `LAILSVSSF`       11        neg        v09                          `LAILSVSSF`   21      neg
  A03       `FVEALFQEY`        11                neg       A01/A03    `MPNDPNRNV`    21            neg                   
  B07/B44   **`RIKPGSANK`**    **38**            **POS**   B07/B58    `IQNSLSTEW`    21            neg                   
            Medium             11                ** **                `SSIGLIMVL`    21            neg                   
                                                                                     `LIMVLSFLF`   26            neg     
                                                                                     Medium        21                    

Peptides were used to stimulate the CD8+ fraction of PBMCs in triplicate, and the number of cells that were actively secreting peptide-specific IFN-ɣ enumerated and expressed as the average number of spot forming cells per million (sfc/m) PBMCs. The presented sfc/m data are the absolute counts and the medium/background responses. response for specific subjects. POS = a positive peptide response, also indicated in bold, neg = negative peptide response.

Discussion {#sec017}
==========

An effective malaria vaccine is essential to the malaria eradication agenda and there is an urgent need to develop cost-effective broad coverage vaccines. A potentially effective and relatively cheaper approach is to identify HLA-restricted immunodominant epitopes from multiple parasite antigens and incorporate these into subunit multi-epitope vaccines. Such epitopes may be identified through bioinformatics prediction of peptide binding by HLA using tools such as NetMHC \[[@pone.0228177.ref026]\], even though not all HLA-bound peptides may be recognized by T cells \[[@pone.0228177.ref027]\]. It is therefore important to experimentally confirm T cell recognition of, and activation by HLA-bound peptides using T cell-based assays such as ELISpot. Using this approach, we have previously identified parasite antigen-specific 15mer peptide pools that elicit potent IFN-ɣ responses when tested against PBMCs from malaria exposed individuals \[[@pone.0228177.ref023]--[@pone.0228177.ref025]\]. It is therefore imperative to further determine the specific peptides within these parasite antigen pools that mediate the induction of these potential protection-associated responses. The aim of this study was therefore to experimentally assess the induction of IFN-γ responses by selected 8-10mer single peptides from *P*. *falciparum* CSP using PBMCs from HLA-typed subjects with natural exposure to malaria.

IFN-ɣ responses (sfc/m) measured in this study were generally of the same order of magnitude as those elicited against CSP peptide pools in individuals from the same naturally exposed population \[[@pone.0228177.ref024]\] but lower than responses achieved in malaria-naïve individuals who have been immunized with CSP-based DNA vaccines \[[@pone.0228177.ref008],[@pone.0228177.ref014]\].

Ten of the 23 peptides (43.5%) elicited positive IFN-ɣ responses in PBMCs from five of the nine HLA-matched study subjects ([Table 2](#pone.0228177.t002){ref-type="table"}), suggesting that the specific HLA alleles expressed by these subjects recognized and presented peptides to T cells. In addition to being predicted as HLA class I-restricted epitopes, six of the ten positive peptides (`LAILSVSSF`, `SFLFVEALF`, `SVSSFLFVEA`, `FLFVEALFQE`, `GLIMVLSFL`, `RIKPGSANK`) also tested positive experimentally in IFN-ɣ ELISpot assays (identified minimal epitopes underlined) with PBMCs from naïve subjects who have been immunized with DNA or peptide-based malaria vaccines \[[@pone.0228177.ref014]\]. `GLIMVLSFL` also tested positive experimentally against PBMCs from individuals naturally exposed to malaria \[[@pone.0228177.ref028]\]. The current data generated with PBMCs from naturally exposed individuals therefore confirms the immunodominant nature of these peptides, even against PBMCs from individuals living in a very low malaria transmission area. The other four identified positive peptides were `YLNKIQNSL`, `IQNSLSTEW`, `MPNDPNRNV` and `HIKEYLNKI`. These peptides are all present in a PfCSP long synthetic peptide (aa282--383) vaccine candidate that elicited significant IFN-ɣ responses in PBMCs from malaria-naïve subjects immunized with this vaccine \[[@pone.0228177.ref029]\]. Confirmation of previously identified immunodominant epitopes and the experimental identification of additional epitopes collectively give relevance to epitope discovery efforts in malaria endemic populations.

Five of the ten positive peptides are located at the N terminal (`LAILSVSSF`, `SVSSFLFVEA`, `SFLFVEALF` and `FLFVEALFQE`, collectively within amino acids 1--30) and C-terminal (GLIMVLSFL, amino acids 386--394) ends of the CSP antigen. The peptide `MPNDPNRNV` (amino acids 285--293) occurs in the central repeat region of the antigen while the other four positive peptides (`IQNSLSTEW`, `HIKEYLNKI`, `YLNKIQNSL` and `RIKPGSANK`) all occur in the middle of the CSP antigen, outside the repetitive region. All ten positive peptides have very limited or no polymorphic residues, but the extent of sequence conservation of these regions of the CSP antigen and their effect on T cell response induction will need to be further investigated.

To confirm the role of CD8+ T cells, PBMCs were enriched for CD8+ T cells by depletion of CD4+ T cells and the efficiency of depletion confirmed using flow cytometry. Four of the ten peptides (17.4%) showed HLA class I restriction following testing against the CD8-enriched PBMC fraction ([Table 3](#pone.0228177.t003){ref-type="table"}). Three of the four peptides (`MPNDPNRNV` and `RIKPGSANK` in subject v03, and `GLIMVLSFL` in subject v04) were amongst the ten previously positive peptides. `RIKPGSANK` also tested positive against the CD8-enriched PBMC fraction from subject v05, but not the unfractionated PBMCs from the same subject. This was also the case for the fourth peptide (`SVFNVVNSSI`); it tested positive with the CD8+ T cell-enriched PBMC fraction but not the unfractionated PBMCs from subject v04. The reason for this observation is unclear, but it is possible that CD8+ T cells in the unfractionated PBMCs from these subjects were inhibited by CD4+ T cells of the regulatory phenotype present in the PBMCs. There is evidence of CD4+ T cell-mediated inhibition of effector T cell responses in *ex vivo* cultures \[[@pone.0228177.ref030]\]. Additionally, reduced immune activity and a consequential early increase in parasite burden in individuals with high levels of CD4+ Treg cells has been demonstrated \[[@pone.0228177.ref031]\]. The observation however may also simply be a result of the responses against the unfractionated PBMCs not meeting the positivity criteria. Although the CD4 depletion kit used in this study may also have depleted some subsets of antigen presenting cells (APCs), the observed response of four out of the ten positive peptides with unfractionated PBMCs suggests that there was effective antigen presentation. This limitation in our approach however indicates that with the full complement of APCs, the CD8+ T cell response to the positive peptides could have been greater in magnitude than was measured. It is also possible that with the full complement of APCs, additional positive peptides. This also reflects in responses to the CEF and Con A positive controls, which are generally lower in the CD8 enriched fractions compared to unfractionated PBMCs.

Two of the four peptides identified as being HLA class I-restricted (`GLIMVLSFL` and `SVFNVVNSSI`) are present in the previously positive peptide pool Cp9 at the C-terminal end of the CSP antigen \[[@pone.0228177.ref024]\]. The two peptides have been predicted by NetMHC to be HLA A02-restricted, and this has been experimentally confirmed in assays with CD8+ T cells from a naturally exposed individual (subject v04) in this study as well as from an immunized malaria-naïve individual \[[@pone.0228177.ref014]\], both of whom express the HLA A02 phenotype. The HLA A02 restriction of `GLIMVLSFL` and its recognition and presentation by other HLA class I supertypes has been demonstrated in sporozoite-immunized as well as naturally exposed subjects \[[@pone.0228177.ref028],[@pone.0228177.ref032]\]. Peptide `SVFNVVNSSI`, aside the observation that it is HLA A02-restricted, has also been predicted to bind to HLA A24 and B27 supertypes in naturally exposed subjects \[[@pone.0228177.ref024]\] and to HLA A01 supertypes in vaccinated malaria naïve subjects \[[@pone.0228177.ref014]\].

The other two peptides that were positive against CD8+ T cell-enriched PBMC fractions have been predicted to be restricted by HLA B07 (`MPNDPNRNV`) and HLA A01A03 and HLA A03 (`RIKPGSANK`), respectively. Subject v03 who responded to both of these peptides correspondingly expresses both the HLA A03 and HLA B07 phenotypes ([Table 3](#pone.0228177.t003){ref-type="table"}). `MPNDPNRNV` has previously been identified as an epitope in subjects from naturally exposed subjects \[[@pone.0228177.ref033],[@pone.0228177.ref034]\] and is present in the CSP peptide pool Cp5 \[[@pone.0228177.ref024]\]. `RIKPGSANK` has been described as an HLA A03-restricted class I epitope that is part of a CSP long synthetic peptide vaccine candidate that elicited potent T cell responses in malaria naïve adults \[[@pone.0228177.ref029]\]; it is also present in peptide pools Cp7/Cp8 \[[@pone.0228177.ref024]\], though none of these two peptide pools have tested positive in our previous assays with PBMCs from malaria exposed individuals. It is however possible that these peptides were presented by promiscuous HLA allele types expressed by subject v03. HLA binding promiscuity is a well-known phenomenon \[[@pone.0228177.ref028],[@pone.0228177.ref035],[@pone.0228177.ref036]\] and that makes the experimental assessment of T cell activation by peptides, beyond bioinformatics predictions, very important. Most of the HLA supertypes that recognize and present the four identified peptides are believed to occur at high frequency in many ethnicities including Africans \[[@pone.0228177.ref027],[@pone.0228177.ref037]\], hence HLA restriction of T cell responses to these peptides may ultimately not be the major obstacle to this T cell-based vaccine development approach.

The seven peptides that tested positive with unfractionated PBMCs but negative with the CD8+ T cell-enriched PBMC fraction have also been predicted by NetMHC to be HLA class I restricted; `LAILSVSSF` (in peptide pool Cp1) is predicted to be HLA B07-, B27- and B58-restricted, `SFLFVEALF` (in pool Cp1) is HLA A24-retricted, `SVSSFLFVEA` and `FLFVEALFQE` (both in pool Cp1) are HLA A02-restricted, `IQNSLSTEW` (in pools Cp6, Cp7) is HLA B27- and HLA B58-restricted, `HIKEYLNKI` (in pool Cp6) is HLA A02- and HLA A01A03-restricted and `YLNKIQNSL` (in pool Cp6) is HLA A02- and B27-restricted \[[@pone.0228177.ref024]\]. As earlier stated, these peptides did not elicit positive IFN-ɣ responses in CD8-enriched PBMC fractions, even though the respective subjects generally express the expected HLA supertypes. This experimental outcome suggests that these peptides may have activated CD4+ T cells in the unfractionated PBMCs. A number of studies have reported a high degree of overlap between HLA class I- and class II-restricted epitopes in *P*. *falciparum* \[[@pone.0228177.ref038]\] as well as other pathogen \[[@pone.0228177.ref039],[@pone.0228177.ref040]\] antigens. This might explain why peptides predicted to be HLA class I-restricted would elicit what appears to be HLA class II-dependent IFN-ɣ responses. Interestingly, six of the seven peptides (`LAILSVSSF`, `SVSSFLFVEA`, `FLFVEALFQE`, `IQNSLSTEW`, `HIKEYLNKI` and `RIKPGSANK`) which were positive against unfractionated PBMCs, but not the CD8+ T cell-enriched PBMC fractions, have previously been confirmed as parts of the sequences of class II-restricted epitopes \[[@pone.0228177.ref038],[@pone.0228177.ref041],[@pone.0228177.ref042]\]. It is also possible that the lack of HLA class I-specific positive responses against these peptides could be due to the fact that the specific HLA class I alleles expressed by our study subjects are different from those that are capable of optimally binding and presenting these peptides to CD8+ T cells.

Some limitations of the current study include our inability to assess the immune status of subjects at the time of drawing blood samples as well as to identify potential infections by PCR as these would have aided the interpretation of study data. Also, we were unable to correspondingly deplete CD8+ T cells and test peptides against CD4+ T cell enriched PBMC fractions due to limited availability of cryopreserved samples. Additionally, it is possible that the CD4+ cell depletion procedure we employed might have depleted some antigen presenting cell subsets, and this could limit the magnitude of responses and hence the number of positive peptides observed. We will in the future employ intracellular cytokine staining methods for performing immune cell subset analysis. These notwithstanding, the data presented make an important contribution to the search for essential parasite targets for vaccine development purposes.

In summary, the study has identified four immunodominant HLA class I-restricted epitopes within the *P*. *falciparum* CSP antigen. All four peptides have been previously reported as epitopes on the basis of experimental data with PBMCs from either vaccinated malaria-naïve subjects or naturally exposed subjects. These epitopes show limited or no polymorphism with the possibility of being recognized and presented to CD8+ T cells by multiple HLA supertypes. A demonstration of anti-malarial protection in naturally exposed individuals as a result of potent T cell responses to these peptides remains to be established. If such protective role is confirmed, these peptides will be important candidates for inclusion in subunit, multi-epitope, strain-transcending, T cell-based malaria vaccines that are capable of inducing IFN-ɣ responses in endemic populations with diverse genetic backgrounds. Our data also reinforces the need to undertake epitope identification studies in naturally exposed individuals as part of malaria vaccine design strategies.

Supporting information {#sec018}
======================

###### Representative histograms of T cell populations before and after CD4+ cell depletion.

PBMCs from eight of the nine study subjects were depleted of cells expressing the CD4 receptor for the purpose of assessing the T cell lineage of peptide-specific IFN- responses. PBMC from all such depletions showed very similar results. Proportions indicate the percentage of total cells gated.

(TIF)

###### 

Click here for additional data file.
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Reviewer \#1: This manuscript addresses the fine mapping of CD8 T cell epitopes on the P. falciparum Circumsporozoite Protein recognised by PBMCs from naturally-exposed Ghanaian donors. This forms a continuation of previous work by the authors in which they already demonstrated recognition of larger peptide pools spanning these epitopes by Ghanaian donors; the majority of these epitopes are also recognised by sporozoite vaccinees. Experimental validation of epitope prediction algorithms is crucial prior to such epitopes being selected for use in a multi-epitope sub-unit pre-erythrocytic malaria vaccine, which may form an alternative to attenuated whole-sporozoite approaches.

As proof of principle, the authors identify several such CD8-restricted epitopes, which moreover appear to be conserved across P.f. strains and may be recognised by multiple HLA supertypes (both of which are advantageous for inclusion in a vaccine). Unfortunately, fewer predicted peptides than perhaps expected could be conclusively shown to be recognised (particularly in the \'CD8-enriched\' cultures, see also below). It is also perhaps slightly concerning that the \'HLA-promiscuous\' epitopes are not recognised more broadly. Finally, as the authors acknowledge, association of any of these epitopes with protection remains to de demonstrated.

The study approach is generally clear and appropriate. The manuscript is well-written and the abstract and discussion balanced, including addressing unexpected results and most limitations. Ethical approval is in place.

The immunological methodology does suffer from some limitations, which presumably can no longer be addressed experimentally, but could perhaps be addressed a little more extensively in the discussion.

Although highly suggestive, the depletion of CD4+ T cells does not conclusively prove that the remaining remaining IFNg must be due to CD8+ T cells. Did the authors not consider depleting CD8-expressing cells in first instance instead of CD4-expressing cells, in order to directly demonstrate CD8+ T cells\' role? An obvious obvious alternative route would have been flow cytometry, but presumably this was not available?

What kit exactly was used for negative selection of CD8+ T cells? The M&M section mentions variously \'\[depleting\] all cell types expressing the CD4 receptor\' and \'a cocktail of \... antibodies against non-CD8+ T cells\'. Depending on this, DCs, monocytes (both of which may also express CD4) and/or B-cells may have been depleted from the PBMCs in addition to CD4+ T cells, limiting the availability of APCs to (cross-)present the peptide to the remaining CD8+ T cells. May this partly explain the lower than expected sfc count in the \'CD8-enriched\' samples compared to whole PBMC samples for many of the peptides (which were all supposed to be MHC-I restricted)? Were responses to CEF also lower in the \'CD8-enriched\' samples?

The authors apply response positivity criteria used and validated in their previous studies. Nevertheless, given (perhaps not unexpectedly) the generally marginal responses to individual peptides (corrected 0-38 sfc/m) in comparison to the range of the neg control (1-24 sfc/m), could the authors in table 2 and 3 maybe provide for each subject the actual sfc value of the neg control for respectively whole PBMC and CD8-enriched cultures? Responses to individual peptides could then be shown either as absolute counts or, as currently, corrected counts. Either way, the reader will be able to form a slightly better impression of the relative strength of individual peptide responses. Were neg control responses generally also lower in the \'CD8-enriched\' samples than the unfractionated samples? May this explain why \'positivity criteria\' for e.g. SVFNVVNSSI were not met in the unfractionated PBMCs?
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Responses to reviewer comments

We thank the reviewer for the very insightful comments, and have provided a point-by-point response to these below;

Reviewer \#1: This manuscript addresses the fine mapping of CD8 T cell epitopes on the P. falciparum Circumsporozoite Protein recognised by PBMCs from naturally-exposed Ghanaian donors. This forms a continuation of previous work by the authors in which they already demonstrated recognition of larger peptide pools spanning these epitopes by Ghanaian donors; the majority of these epitopes are also recognised by sporozoite vaccinees. Experimental validation of epitope prediction algorithms is crucial prior to such epitopes being selected for use in a multi-epitope sub-unit pre-erythrocytic malaria vaccine, which may form an alternative to attenuated whole-sporozoite approaches.

Reviewer comment

As proof of principle, the authors identify several such CD8-restricted epitopes, which moreover appear to be conserved across P.f. strains and may be recognised by multiple HLA supertypes (both of which are advantageous for inclusion in a vaccine). Unfortunately, fewer predicted peptides than perhaps expected could be conclusively shown to be recognised (particularly in the \'CD8-enriched\' cultures, see also below). It is also perhaps slightly concerning that the \'HLA-promiscuous\' epitopes are not recognised more broadly. Finally, as the authors acknowledge, association of any of these epitopes with protection remains to be demonstrated.

Response

Only a very limited number of peptides (between 3 and 8) were tested against PBMCs from each of the 9 study volunteers (due to limited cell numbers). We therefore did not expect to identify many epitopes per individual. What we sought to show is how many of the positive peptides with whole PBMCs are HLA class I-restricted, since there is also the possibility of having some of the immunodominant epitopes to be HLA class II-restricted.

The HLA diversity in these 9 volunteers may be too limited to actually demonstrate binding promiscuity. It is also important to note that promiscuity in HLA binding as described in the manuscript is mostly based on predictive algorithms which have been duly referenced and not necessarily on experimental data.

Regarding the statement on association with protection, we used PBMCs from adult volunteers with a history of natural exposure to malaria infections, but we did not have any information on their antimalarial protection status, hence that statement. We are currently working on addressing this, in a study where we have recruited people with a history of recent exposure to infectious bites and sometimes even show malaria parasites in the blood (an indication of a completed liver stage cycle) but with no clinical symptoms of malaria. Thus in our current on-going study, we have defined "protection" as evidence of exposure to recent infectious bites that do not result in clinical malaria symptoms.

Reviewer comment

The study approach is generally clear and appropriate. The manuscript is well-written and the abstract and discussion balanced, including addressing unexpected results and most limitations. Ethical approval is in place.

The immunological methodology does suffer from some limitations, which presumably can no longer be addressed experimentally, but could perhaps be addressed a little more extensively in the discussion.

Response: We have included additional study limitations and how they impact the presented data to the discussion section.

Although highly suggestive, the depletion of CD4+ T cells does not conclusively prove that the remaining IFNg must be due to CD8+ T cells. Did the authors not consider depleting CD8-expressing cells in first instance instead of CD4-expressing cells, in order to directly demonstrate CD8+ T cells\' role? An obvious alternative route would have been flow cytometry, but presumably this was not available?

Response

We initially considered testing both CD8-enriched and CD4 enriched T cells for comparison with whole PBMCs, but had to go with just one of them because of the limited cell numbers

Reviewer comment

What kit exactly was used for negative selection of CD8+ T cells? The M&M section mentions variously \'\[depleting\] all cell types expressing the CD4 receptor\' and \'a cocktail of \... antibodies against non-CD8+ T cells\'. Depending on this, DCs, monocytes (both of which may also express CD4) and/or B-cells may have been depleted from the PBMCs in addition to CD4+ T cells, limiting the availability of APCs to (cross-)present the peptide to the remaining CD8+ T cells. May this partly explain the lower than expected sfc count in the \'CD8-enriched\' samples compared to whole PBMC samples for many of the peptides (which were all supposed to be MHC-I restricted)? Were responses to CEF also lower in the \'CD8-enriched\' samples?

Response

We used the anti-human MyOne^™^ SA Dynabeads® kit (Invitrogen, Life Technologies) for CD8 T cell enrichment, and we agree with the reviewer regarding depletion of some antigen presenting cells (APCs) along with CD4 T cells since some APC subsets may also express the targeted receptors. It is however important to note that some other APC subsets likely to remain to undertake antigen cross-presentation, although we agree with the reviewer that these might have lowered the observed epitope positivity rate. This would then mean that our responses could have been stronger than observed, in the presence of the full complement of APCs.

All volunteers responded positively to the at least of the three positive controls

Reviewer comment

The authors apply response positivity criteria used and validated in their previous studies. Nevertheless, given (perhaps not unexpectedly) the generally marginal responses to individual peptides (corrected 0-38 sfc/m) in comparison to the range of the neg control (1-24 sfc/m), could the authors in table 2 and 3 maybe provide for each subject the actual sfc value of the neg control for respectively whole PBMC and CD8-enriched cultures? Responses to individual peptides could then be shown either as absolute counts or, as currently, corrected counts. Either way, the reader will be able to form a slightly better impression of the relative strength of individual peptide responses. Were neg control responses generally also lower in the \'CD8-enriched\' samples than the unfractionated samples? May this explain why \'positivity criteria\' for e.g. SVFNVVNSSI were not met in the unfractionated PBMCs?

Response

We agree with the reviewer and have provided the respective medium/background control values in Tables 2 and 3. We have therefore reverted to absolute counts (without background subtraction) for each stimulant in these two tables. We have also incorporated data on the positive control and background counts for assays with CD8+ T cell enriched PBMCs in the results section.
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Following review both by myself and an expert reviewer, the revised manuscript is now deemed acceptable for publication.

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the "Comments to the Author" section, enter your conflict of interest statement in the "Confidential to Editor" section, and submit your \"Accept\" recommendation.
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2\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: (No Response)

\*\*\*\*\*\*\*\*\*\*

3\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: (No Response)
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4\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: (No Response)
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5\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: (No Response)
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6\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: Many thanks to the authors for addressing my comments in their response and modifying the Results and Discussion section of the manuscript accordingly. This is now acceptable for publication as-is.

I have one final comment/question regarding the authors\' definition of protection in their future studies. How do you prove evidence of \'exposure to recent infectious bites\' unless you have conducted a controlled human malaria infection on these subjects and then dissect the mosquitoes?? Otherwise you can only assume that the subject was actually bitten. If you are basing this evidence on the presence of circulating blood-stage parasites (which does not necessarily imply \'recent\' exposure, but that aside), then in practice your definition of protection equates to having asymptomatic parasitaemia. Although this is a potential indicator of clinical immunity/protection, it is a curious definition to use if you are investigating immune responses against a pre-erythrocytic antigen such as CSP. There you would presumably expect \'protection\' to prevent the liver stage cycle from being completed, thus actually avoiding the appearance of blood-stage parasites - the precise opposite of your definition.
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If you choose "no", your identity will remain anonymous but your review may still be made public.
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